Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2009 1
2012 1
2013 1
2014 6
2015 20
2016 50
2017 70
2018 97
2019 110
2020 170
2021 207
2022 188
2023 166
2024 156

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. Mancia G, et al. J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26. J Hypertens. 2023. PMID: 37345492
Hypertension management in patients with cardiovascular comorbidities.
Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, Parati G, Rossignol P, Schlaich MP, Teo KK, Townsend RR, Tsioufis C, Weber MA, Weber T, Böhm M. Lauder L, et al. Eur Heart J. 2023 Jun 20;44(23):2066-2077. doi: 10.1093/eurheartj/ehac395. Eur Heart J. 2023. PMID: 36342266 Review.
Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin-angiotensin system blockers, calcium channel blockers, and/or a …
Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Gui …
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week.
Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, Ponikowski P, Voors AA, Zannad F, Zieroth S, Butler J. Greene SJ, et al. J Am Coll Cardiol. 2023 Jan 31;81(4):413-424. doi: 10.1016/j.jacc.2022.11.023. J Am Coll Cardiol. 2023. PMID: 36697141 Free article. Review.
The definition of WHF continues to evolve from a historical focus solely on hospitalization to now include nonhospitalization events (eg, need for intravenous diuretic therapy in the emergency or outpatient setting). Most HF clinical trials to date have had HF hospitalizat …
The definition of WHF continues to evolve from a historical focus solely on hospitalization to now include nonhospitalization events (eg, ne …
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, Agarwal R, Mark PB, Kotanko P, Ferro CJ, Wanner C, Burnier M, Vanholder R, Wiecek A. Zoccali C, et al. Cardiovasc Res. 2023 Sep 5;119(11):2017-2032. doi: 10.1093/cvr/cvad083. Cardiovasc Res. 2023. PMID: 37249051 Free PMC article. Review.
Because of the high death rate attributable to cardiovascular (CV) disease, most patients with progressive CKD die before reaching kidney failure. ...Sodium/glucose cotransporter-2 inhibitors are now fully emerged as a class of drugs that substantially reduces the risk for …
Because of the high death rate attributable to cardiovascular (CV) disease, most patients with progressive CKD die before reaching ki …
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure.
Ferreira JP, Sharma A, Butler J, Packer M, Zannad F, Vasques-Nóvoa F, Leite-Moreira A, Neves JS. Ferreira JP, et al. J Clin Endocrinol Metab. 2023 Dec 21;109(1):4-9. doi: 10.1210/clinem/dgad398. J Clin Endocrinol Metab. 2023. PMID: 37409733 Free article. Review.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. ...Aft …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body weight in overweight or people with obesity and to impro …
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, Tromp J, Ferreira JP, Nassif ME, Psotka MA, Brueckmann M, Salsali A, Blatchford JP, Ponikowski P. Biegus J, et al. Eur Heart J. 2023 Jan 1;44(1):41-50. doi: 10.1093/eurheartj/ehac530. Eur Heart J. 2023. PMID: 36254693 Free PMC article. Clinical Trial.
METHODS AND RESULTS: A total of 530 patients hospitalized for AHF were randomized 1:1 to either empagliflozin 10 mg once daily or placebo for 90 days. The outcomes investigated were: weight loss (WL), WL adjusted for mean daily loop diuretic dose (WL-adjusted), area under …
METHODS AND RESULTS: A total of 530 patients hospitalized for AHF were randomized 1:1 to either empagliflozin 10 mg once daily or placebo fo …
Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3.
Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Filippatos G, Gustafsson F, Lam CSP, Lund LH, Mentz RJ, Pieske B, Ponikowski P, Senni M, Skopicki N, Voors AA, Zannad F, Zieroth S, Butler J. Greene SJ, et al. J Am Coll Cardiol. 2023 Aug 8;82(6):559-571. doi: 10.1016/j.jacc.2023.04.057. J Am Coll Cardiol. 2023. PMID: 37532426 Free article. Review.
Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline is despite a rapi …
Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedic …
From Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition.
Zoccali C, Mallamaci F, Halimi JM, Rossignol P, Sarafidis P, De Caterina R, Giugliano R, Zannad F. Zoccali C, et al. Clin J Am Soc Nephrol. 2024 Jun 1;19(6):813-820. doi: 10.2215/CJN.0000000000000361. Epub 2023 Oct 30. Clin J Am Soc Nephrol. 2024. PMID: 37902772 Review.
We apply Occam's razor to the chronology-based construct to arrive at a simple definition on the basis of the coexistence of cardiovascular disease and CKD, the chronic cardiovascular-kidney disorder (CCKD). This conceptual framework builds upon the fact that car …
We apply Occam's razor to the chronology-based construct to arrive at a simple definition on the basis of the coexistence of cardiovascul …
Diagnosis of cardiovascular disease in patients with chronic kidney disease.
Zoccali C, Mark PB, Sarafidis P, Agarwal R, Adamczak M, Bueno de Oliveira R, Massy ZA, Kotanko P, Ferro CJ, Wanner C, Burnier M, Vanholder R, Mallamaci F, Wiecek A. Zoccali C, et al. Nat Rev Nephrol. 2023 Nov;19(11):733-746. doi: 10.1038/s41581-023-00747-4. Epub 2023 Aug 23. Nat Rev Nephrol. 2023. PMID: 37612381 Review.
Patients with chronic kidney disease (CKD) are at high risk of cardiovascular disease (CVD) and cardiovascular death. Identifying and monitoring cardiovascular complications and hypertension is important for managing patients with CKD or kidney failure and tr …
Patients with chronic kidney disease (CKD) are at high risk of cardiovascular disease (CVD) and cardiovascular death. Identify …
Assessment of filling pressures and fluid overload in heart failure: an updated perspective.
de la Espriella R, Cobo M, Santas E, Verbrugge FH, Fudim M, Girerd N, Miñana G, Górriz JL, Bayés-Genís A, Núñez J. de la Espriella R, et al. Rev Esp Cardiol (Engl Ed). 2023 Jan;76(1):47-57. doi: 10.1016/j.rec.2022.07.009. Epub 2022 Aug 4. Rev Esp Cardiol (Engl Ed). 2023. PMID: 35934293 Review. English, Spanish.
However, its severity and organ and compartment distribution vary widely among patients, illustrating the complexity of this phenomenon. Although clinical symptoms and signs are useful to assess congestion and manage volume status in individual patients, they have limited …
However, its severity and organ and compartment distribution vary widely among patients, illustrating the complexity of this phenomenon. Alt …
166 results